Corporate & Securities

Joint Ventures, Strategic Alliances, Collaborations & Technology Transfer

When thinking about entering into a partnership to develop your company or your product line, it’s crucial to consider the business, financial, and legal implications. Whether you are a company or individual in the life sciences or technology industry, you need counsel who is familiar with the ins and outs of your business so you can benefit from the most solidly structured agreement possible.

Our attorneys are regarded as some of the most knowledgeable attorneys in negotiating agreements for joint venture and collaborative research; development, services, and university licensing arrangements; and other agreements to develop new products and technology. Our attorneys’ knowledge of business, communications, technology, and intellectual property law allows them to provide exceptional business-focused legal advice in these complicated transactions. We will work closely with you to structure and implement a transaction that builds upon your strengths and fills the gaps where needed.

Quick Facts

  • National Tier 1 ranking for Technology Law and Biotechnology Law by US News & World Report and Best Lawyers in “Best Law Firms” (2014)
  • Integrated intellectual property, licensing, and corporate practice
  • "Licensing and Collaborations Firm of the Year" by LMG Life Sciences (2013)
  • Assist clients in bringing their products from the research laboratory to the commercial market
  • Structure and implement technology-based transactions
  • Dozens of licensing / collaboration transactions since 2012, with an aggregate deal value of close to $5 billion

Areas of Focus

  • Advertising issues
  • Business continuity and master recovery
  • Data security and privacy
  • Development and collaboration arrangements
  • Distributorship agreements
  • Establishment, sourcing, procurement, and Implementation of IT systems and services
  • In-licensing of technology from universities and research institutions
  • Intellectual property protection and enforcement programs
  • Internet transactions and Internet liability issues
  • Outsourcing transactions
  • Strategic alliances and joint ventures

Sort by: Name  Title  Office

Priya K. Agrawal

Priya K. Agrawal


New York 212.692.6708
New York 212.692.6869
Boston 617.348.1742
Hannah C. Coman

Hannah C. Coman


Boston 617.348.1703
Boston 617.348.4716
Boston 617.348.1670
Boston 617.348.1797
Robert Duggan

Robert Duggan


Boston 617.348.1780
London, UK +44.20.7776.7330
London, UK 011.44.790.881.9030
Kristin A. Gerber

Kristin A. Gerber


Boston 617.348.3043
Boston 617.348.1650
Boston 617.348.1654
Sarah T. Hogan

Sarah T. Hogan


Boston 617.348.1883
Boston 617.348.1638
San Diego 858.314.1525
Boston 617.348.1732
Mark Nemes

Mark Nemes


New York 212.692.6718
San Diego 858.314.1527
Los Angeles 310.586.3200
San Francisco 415.432.6080
San Diego 858.314.1873
Boston 617.348.3039
Anne L. Strassner

Anne L. Strassner

Of Counsel

New York 212.692.6280
San Diego 858.314.1559
San Francisco 415.432.6000
Christine M. Wahr

Christine M. Wahr


Boston 617.348.3014
Boston 617.348.1869
Boston 617.348.1759

Representative Experience

  • Represented Inhibrx LLC in its June 2012 Option and License Agreement with Celgene Corporation.
  • Represented GreatPoint Energy, Inc. in its March 2012 $400 million Series D financing led by China Wanxiang Holding Co. Ltd.
  • Represented Angiochem, Inc. in its February 2012 collaboration with GlaxoSmithKline (GSK).
  • Represented Intarcia Therapeutics, Inc. in its December 2011 strategic alliance with Quintiles.
  • Represented ArQule, Inc. (NASDAQ: ARQL) in the November 2011 execution of a license agreement with Daiichi Sankyo, Co. Ltd.
  • Represented BeiGene, LLC on the exclusive in-licensing and co-development agreements of October 2011 with Janssen Pharmaceutica NV and CNA Development, LLC, divisions of Johnson & Johnson (NYSE: JNJ).